Marstacimab

CAS No. 1985638-39-8

Marstacimab( —— )

Catalog No. M37307 CAS No. 1985638-39-8

Marstacimab (PF-06741086), an anti-tissue factor pathway inhibitor (TFPI) monoclonal antibody, is utilized in hemophilia research .

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 687 In Stock
10MG 937 In Stock
25MG 1416 In Stock
50MG 1832 In Stock
100MG Get Quote In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    Marstacimab
  • Note
    Research use only, not for human use.
  • Brief Description
    Marstacimab (PF-06741086), an anti-tissue factor pathway inhibitor (TFPI) monoclonal antibody, is utilized in hemophilia research .
  • Description
    Marstacimab (PF-06741086) is an anti-tissue factor pathway inhibitor (TFPI) monoclonal antibody. Marstacimab can be used for the research of hemophilia.
  • In Vitro
    ——
  • In Vivo
    Animal Model:Acute bleeding hemophilia A mouse modelsDosage:0.5 mg/kg Administration:Intravenous injection, 0.5 mg/kg, once, before tail clip Result:Showed no effect on the blood loss compared with control mice, but significantly reduced the blood loss with the combination of aPCC 200 U/kg.
  • Synonyms
    ——
  • Pathway
    Others
  • Target
    Other Targets
  • Recptor
    Others
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    1985638-39-8
  • Formula Weight
  • Molecular Formula
    ——
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    ——
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Patel-Hett S, et al. Marstacimab, a tissue factor pathway inhibitor neutralizing antibody, improves coagulation parameters of ex vivo dosed haemophilic blood and plasmas. Haemophilia. 2019 Sep;25(5):797-806.?
molnova catalog
related products